University of Liverpool, Liverpool, England;
University Hospital Aintree, Liverpool
Objectives: While the crucial role of epigenetics in cancer is now being realized, this field has not yet been exploited for clinical benefit in head and neck squamous cell carcinoma (HNSCC). Our objective was to evaluate the biomarker possibilities of DNA promoter methylation.
Patients: Seventy-nine patients with HNSCC undergoing surgical resection.
Shaw RJ, Hall G, Liloglou T, et al. P182 Clinical Application of Epigenetic Biomarkers in Head and Neck Cancer. Arch Otolaryngol Head Neck Surg. 2006;132(8):900–901. doi:10.1001/archotol.132.8.900-c
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: